Page 25 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Progress in the research of pathology and therapy in liver fibrosis

and steatohepatitis in a diet induced animal model of doi: 10.3389/fcell.2021.716842
nonalcoholic fatty liver disease. Sci Rep. 2020;10(1):9330.
105. Tan HX, Gong WZ, Zhou K, et al. CXCR4/TGF-β1 mediated
doi: 10.1038/s41598-020-66458-z hepatic stellate cells differentiation into carcinoma-
associated fibroblasts and promoted liver metastasis of colon
95. Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al. Proof- cancer. Cancer Biol Ther. 2020;21(3):258-268.
of-concept study to evaluate the safety and efficacy of
saroglitazar in patients with primary biliary cholangitis. doi: 10.1080/15384047.2019.1685157
J Hepatol. 2022;76(1):75-85. 106. Li R, Li Z, Feng Y, et al. PDGFRβ-targeted TRAIL specifically
doi: 10.1016/j.jhep.2021.08.025 induces apoptosis of activated hepatic stellate cells and
ameliorates liver fibrosis. Apoptosis. 2020;25(1-2):105-119.
96. Lefere S, Puengel T, Hundertmark J, et al. Differential
effects of selective- and pan-PPAR agonists on experimental doi: 10.1007/s10495-019-01583-3
steatohepatitis and hepatic macrophages☆. J Hepatol. 107. Ribera J, Vilches C, Sanz V, et al. Treatment of hepatic
2020;73(4):757-770. fibrosis in mice based on targeted plasmonic hyperthermia.
doi: 10.1016/j.jhep.2020.04.025 ACS Nano. 2021;15(4):7547-7562.
97. Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al. Pan- doi: 10.1021/acsnano.1c00988
PPAR agonist lanifibranor improves portal hypertension 108. Samuelsson E, Shen H, Blanco E, Ferrari M, Wolfram J.
and hepatic fibrosis in experimental advanced chronic liver Contribution of Kupffer cells to liposome accumulation in
disease. J Hepatol. 2021;74(5):1188-1199. the liver. Colloids Surf B Biointerfaces. 2017;158:356-362.
doi: 10.1016/j.jhep.2020.11.045 doi: 10.1016/j.colsurfb.2017.07.014
98. Møllerhøj MB, Veidal SS, Thrane KT, et al. Hepatoprotective 109. Ullah A, Wang K, Wu P, Oupicky D, Sun M. CXCR4-
effects of semaglutide, lanifibranor and dietary intervention targeted liposomal mediated co-delivery of pirfenidone and
in the GAN diet-induced obese and biopsy-confirmed mouse AMD3100 for the treatment of TGFβ-induced HSC-T6 cells
model of NASH. Clin Transl Sci. 2022;15(5):1167-1186. activation. Int J Nanomedicine. 2019;14:2927-2944.
doi: 10.1111/cts.13235 doi: 10.2147/IJN.S171280
99. Francque SM, Bedossa P, Ratziu V, et al. A Randomized, 110. Fan QQ, Zhang CL, Qiao JB, et al. Extracellular matrix-
controlled trial of the Pan-PPAR agonist lanifibranor in penetrating nanodrill micelles for liver fibrosis therapy.
NASH. N Engl J Med. 2021;385(17):1547-1558. Biomaterials. 2020;230:119616.
doi: 10.1056/NEJMoa2036205 doi: 10.1016/j.biomaterials.2019.119616
100. Lin TT, Gao DY, Liu YC, et al. Development and 111. Zhang LF, Wang XH, Zhang CL, et al. Sequential
characterization of sorafenib-loaded PLGA nanoparticles nano-penetrators of capillarized liver sinusoids and
for the systemic treatment of liver fibrosis. J Control Release. extracellular matrix barriers for liver fibrosis therapy. ACS
2016;221:62-70. Nano. 2022;16(9):14029-14042.
doi: 10.1016/j.jconrel.2015.11.003 doi: 10.1021/acsnano.2c03858
101. Peng F, Tee JK, Setyawati MI, et al. Inorganic nanomaterials 112. Zhou L, Liang Q, Li Y, et al. Collagenase-I decorated
as highly efficient inhibitors of cellular hepatic fibrosis. ACS co-delivery micelles potentiate extracellular matrix
Appl Mater Interfaces. 2018;10(38):31938-31946. degradation and hepatic stellate cell targeting for liver
doi: 10.1021/acsami.8b10527 fibrosis therapy. Acta Biomater. 2022;152:235-254.

102. Tran HT, Vong LB, Nishikawa Y, Nagasaki Y. Sorafenib- doi: 10.1016/j.actbio.2022.08.065
loaded silica-containing redox nanoparticles for oral anti- 113. Wu J, Xue X, Fan G, et al. Ferulic acid ameliorates hepatic
liver fibrosis therapy. J Control Release. 2022;345:880-891. inflammation and fibrotic liver injury by inhibiting PTP1B
doi: 10.1016/j.jconrel.2022.04.002 activity and subsequent promoting AMPK phosphorylation.
Front Pharmacol. 2021;12:754976.
103. Hong F, Tuyama A, Lee TF, et al. Hepatic stellate cells
express functional CXCR4: role in stromal cell-derived doi: 10.3389/fphar.2021.754976
factor-1alpha-mediated stellate cell activation. Hepatology. 114. Cheng Q, Li C, Yang CF, et al. Methyl ferulic acid attenuates
2009;49(6):2055-2067. liver fibrosis and hepatic stellate cell activation through
the TGF-β1/Smad and NOX4/ROS pathways. Chem Biol
doi: 10.1002/hep.22890
Interact. 2019;299:131-139.
104. Wang S, Gao S, Li Y, Qian X, Luan J, Lv X. Emerging
importance of chemokine receptor CXCR4 and its ligand in doi: 10.1016/j.cbi.2018.12.006
liver disease. Front Cell Dev Biol. 2021;9:716842. 115. Xue T, Yue L, Zhu G, et al. An oral phenylacrylic acid

Volume 9 Issue 3 (2025) 17 doi: 10.36922/ejmo.8125